Poxel Investor Relations Material
Latest events
H1 2023
Poxel
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Poxel S.A.
Access all reports
Poxel S.A. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases, particularly those related to metabolic disorders. The company's research pipeline includes treatments for conditions like non-alcoholic steatohepatitis (NASH) and rare metabolic diseases such as adrenoleukodystrophy (ALD). Poxel leverages proprietary platforms including adenosine monophosphate-activated protein kinase (AMPK) activators and deuterated thiazolidinedione (TZD) compounds. The company is headquartered in Lyon, France, with additional offices in Boston, Massachusetts, and Tokyo, Japan. Its shares are listed on Euronext Paris.
Latest articles
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
POXEL
Country
🇫🇷 France